Drug Review Decisions

The Drug Review Results search tool lets you search for a specific drug to find out if it is under review and where it is in the review process, or if and when PharmaCare decided to cover it, and if so, under which PharmaCare plan.

In the Drug Reviews table, you will find a list of drugs reviewed by PharmaCare, and a summary of each review’s outcome (PDF). The summary notes the reasons, such as clinical evidence and cost, that a drug is or is not covered by PharmaCare.

Therapeutic and Program Reviews include drug decision summaries, clinical and pharmacoeconomic evidence reports, and Drug Benefit Council recommendations for drugs for particular conditions and the drugs in the Reference Drug Program.  

The  Drug Review Results search tool gives information on

  • all drugs reviewed by the national Common Drug Review (CDR) and submitted to the Ministry of Health for consideration;
  • all drug reviews completed by the Ministry since 2005; and
  • brand name drugs currently under review by the Ministry and the CDR, including
    • the drug's brand name, chemical name, and manufacturer
    • the drug's indication (the condition it treats)
    • the date when the drug was submitted to the Ministry
    • the date the drug was discussed by the Drug Benefit Council (DBC) (after October 2009)
    • whether the drug was reviewed by the CDR
    • the date the CDR made its recommendation
    • the drug's PharmaCare program status (e.g., under review, non-benefit)
    • the date on which the Ministry's decision was made

Information on generic drug reviews is not included.

For more on the benefit status of drugs not found through Drug Review Results, please use the PharmaCare Formulary Search.

Any column in this table can be alphabetically sorted. Drugs that have not been reviewed, or were reviewed before 2008, will not appear in this table. 

Decision Summaries
Generic Name Brand Name Indication PharmaCare Decision Dates and Summaries
abatacept (SQ) Orencia® rheumatoid arthritis February 25, 2014
abobotulinumtoxinA Dysport Therapeutic™ cervical dystonia (spasmodic torticollis) and focal spasticity February 26, 2019
aclidinium Tudorza™; Genuair™ chronic obstructive pulmonary disease (COPD) September 30, 2014
aclidinium bromide-formoterol fumarate dehydrate Duaklir™; Genuair® chronic obstructive pulmonary disease (COPD) April 5, 2016
adalimumab Humira® difficult-to-treat Crohn's disease September 9, 2008
adalimumab Humira® juvenile idiopathic arthritis February 25, 2014
adalimumab Humira® ulcerative colitis June 20, 2017
adalimumab Humira® hidradenitis suppurativa (HS) April 18, 2017
adalimumab Humira® hidradenitis suppurativa (HS) March 6, 2018
adefovir Hepsera® chronic hepatitis B November 27, 2018
alemtuzumab Lemtrada™ relapsing-remitting multiple sclerosis (RRMS) February 6, 2018
alirocumab Praluent™ Treatment of high-risk adult patients who have had prior cardiovascular (CV) events and require additional lowering of low density lipoprotein cholesterol (LDL-C) January 28, 2020
alogliptin Nesina™  type 2 diabetes mellitus  May 5, 2015
alogliptin-metformin Kazano™ type 2 diabetes mellitus  May 5, 2015
apixaban Eliquis® stroke prophylaxis in atrial fibrillation September 19, 2013
apixaban Eliquis® prevention of venous thromboembolic events December 10, 2013
apixaban Eliquis® thromboembolic events (venous), treatment and prevention of recurrence April 5, 2016
apomorphine Movapo™ Advanced Parkinson’s disease November 26, 2019
apremilast Otezla moderate to severe plaque psoriasis October 10, 2017
apremilast Otezla psoriatic arthritis October 10, 2017
aprepitant Emend® for prevention of vomiting in patients with cancer March 16, 2010
aripiprazole Abilify® major depressive disorder (MDD) April 14, 2015
aripiprazole monohydrate Abilify Maintena™ schizophrenia August 11, 2015
asunaprevir Sunvepra™ chronic hepatitis C (CHC) March 21, 2017
azelastine hydrochloride – fluticasone propionate Dymista® moderate to severe seasonal allergic rhinitis and associated ocular symptoms September 29, 2015
azilsartan Edarbi hypertension, essential July 29, 2014
azilsartan Edarbyclor hypertension, essential July 29, 2014
benralizumab Fasenra® severe eosinophilic asthma April 1, 2020
boceprevir Victrelis™ HIV/hepatitis C October 10, 2013
brexpiprazole Rexulti® For the treatment of schizophrenia December 17, 2019
brinzolamide-brimonidine Simbrinza® glaucoma and ocular hypertension October 27, 2015
brodulamab Siliq™ plaque psoriasis November 27, 2018
budesonide Cortiment®MMX induction of remission in patients with active, mild to moderate ulcerative colitis June 13, 2017
buprenorphine-naloxone Suboxone® opioid drug dependence in adults October 13, 2015
buprenorphine hydrochloride Probuphine™ management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support February 25, 2020
canakinumab Ilaris® active systemic juvenile idiopathic arthritis (sJIA) in patients aged two years and older January 10, 2017
certolizumab pegol Cimzia® arthritis, psoriatic February 19, 2016
certolizumab pegol Cimzia® ankylosing spondylitis February 19, 2016
ciprofloxacin + dexamethasone (ear drops) Ciprodex® acute otitis media with otorrhea and otitis externa January 16, 2009
clopidogrel (1) Plavix® after drug-eluting stent insertion February 18, 2008
clopidogrel (2) Plavix® acute coronary syndrome March 20, 2020
clostridium botulinum neurotoxin type A, with complexing proteins Xeomin® muscle spasticity June 15, 2010
colesevelam hydrochloride Lodalis hypercholesterolemia June 13, 2013
collagenase clostridium histolyticum Xiaflex™ Dupuytren’s contracture with a palpable cord March 25, 2014
crisaborole Eucrisa™ Atopic dermatitis January 14, 2020
daclatasvir Daklinza™ chronic hepatitis C (CHC) March 13, 2018
deferiprone Ferriprox™ transfusional iron overload due to thalassemia syndromes October 25, 2016
delta-9-tetrahydrocannabinol + cannabidiol (1) Sativex® adjunctive neuropathic pain relief in multiple sclerosis December 23, 2008
delta-9-tetrahydrocannabinol + cannabidiol (2) Sativex® adjunctive pain relief in advanced cancer December 23, 2008
denosumab Prolia® for the treatment of men with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy February 14, 2017
denosumab Xgeva prevention of skeletal-related events due to bone metastases from solid tumours January 17, 2017
dexamethasone Ozurdex® diabetic macular edema February 26, 2019
dimethyl fumerate Tecfidera™ multiple sclerosis, relapsing June 24, 2014
doxycycline Apprilon® rosacea January 28, 2014
dulaglutide Trulicity® type 2 diabetes March 13, 2020
duloxetine generics neuropathic pain November 27, 2018
dupilumab Dupixent™ atopic dermatitis January 22, 2019
eculizumab Soliris® hemolytic-uremic syndrome, atypical January 14, 2014
edoxaban Lixiana® stroke and blood clot prevention in atrial fibrillation;  treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) March 26, 2019
efinaconazole Jublia™ fungal infection (onychomycosis) caused by certain fungi (Trichophyton species) March 3, 2020
elbasvir-grazoprevir Zepatier® chronic hepatitis C (CHC) March 13, 2018
elosulfase alfa Vimizim™ Mucopolysaccharidosis type IVA (MPS IVA or Morquio A syndrome) September 22, 2015
eltrombopag Revolade® chronic hepatitis C associated thrombocytopenia (low platelet counts) July 14, 2015
eluxadoline Viberzi™ irritable bowel syndrome June 11, 2019
empagliflozin Jardiance™ type 2 diabetes mellitus (T2DM) May 27, 2019
entecavir Baraclude® chronic hepatitis B November 27, 2018
eplerenone Inspra® heart failure, NYHA class II November 18, 2014
eslicarbazepine acetate Afinitor® epilepsy, partial-onset seizures November 10, 2015
etanercept Brenzys™; Erelzi™; Enbrel® rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis May 27, 2019
etanercept Erelzi™ psoriatic arthritis April 9, 2019
etanercept Brenzys™ rheumatoid arthritis (RA); ankylosing spondylitis (AS) July 18, 2017
etanercept Erelzi™ rheumatoid arthritis, ankylosing spondylitis and polyarticular juvenile idiopathic arthritis November 14, 2017
etidronate (in combination with calcium carbonate) Didrocal
ACT-etidrocal
prevention of fractures due to osteoporosis February 19, 2019
everolimus (1) Afinitor® renal angiomyolipoma associated with tuberous sclerosis complex (TSC) August 12, 2014
everolimus (2) Afinitor® subependymal giant cell astrocytoma (SEGA), a brain tumour associated with a genetic condition called tuberous sclerosis complex (TSC) July 28, 2015
evolocumab Repatha® clinical artherosclerotic cardiovascular disease (ASCVD) March 10, 2020
evolocumab Repatha® heterozygous familial hypercholesterolemia December 18, 2018
exenatide Byetta type 2 diabetes mellitus  June 20, 2013
ezetimibe Ezetrol® hypercholesterolemia December 18, 2018
ezetimibe Ezetrol® high cholesterol in patients with specific variants of NPC1L1 protein September 27, 2007
fampridine Fampyra® multiple sclerosis, improve walking ability June 20, 2013
fentanyl buccal/sublingual Fentora® management of breakthrough pain in adult cancer patients with difficulty swallowing or inadequate pain relief/intolerance/contraindication to morphine, oxycodone or hydromorphone May 16, 2017
fesoterodine fumarate Toviaz overactive bladder August 4, 2016
fidaxomicin Dificid® Clostridium difficile infection February 25, 2014
filgrastim Grastofil® prevention/treatment of neutropenia January 31, 2017
filgrastim Grastofil® primary prophylaxis of febrile neutropenia in cancer patients receiving potentially curative myelosuppressive chemotherapy regimens where the risk of febrile neutropenia is ≥ 20% October 16, 2018 
filgrastim Grastofil® pre-filled sterile solution for injection January 31, 2017
fluorouracil and salicyclic acid Actikerall™ slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients March 20, 2018
fluticasone furoate Arnuity™; Ellipta® asthma September 13, 2016
fluticasone furoate-vilanterol Breo®; Ellipta® chronic obstructive pulmonary disease (COPD) May 15, 2015
fluticasone furoate-vilanterol Breo®; Ellipta® asthma September 13, 2016
fluticasone propionate Aermony RespiClick™ for the treatment of asthma in patients 12 years or older February 11, 2020
fluticasone propionate/salmeterol xinafoate Arbesda RespiClick™ for the treatment of asthma in patients 12 years or older February 11, 2020
fosfomycin Monurol® uncomplicated urinary tract infections March 24, 2015
glatiramer acetate Copaxone® relapsing remitting multiple sclerosis. March 17, 2020
glatiramer acetate Glatect™ relapsing remitting multiple sclerosis November 27, 2018
glecaprevir-pibrentasvir Maviret™ chronic hepatitis C March 21, 2019 and January 29, 2019
gliclazide Diamicron® type 2 diabetes July 8, 2008
glycopyrronium Seebri® chronic obstructive pulmonary disease (COPD) September 19, 2013
golimumab Simponi ulcerative colitis May 31, 2016 
golimumab Simponi®; Intravenous (IV) rheumatoid arthritis (RA) May 31, 2016
grass pollen allergen extract Oralair™ allergic rhinitis (grass pollen) October 31, 2013
icatibant Firazyr® angioedema February 6, 2018
imiquimod Aldara® actinic keratosis on the face or balding scalp June 28, 2010
indacaterol Onbrez® chronic obstructive pulmonary disease (COPD), maintenance bronchodilator treatment May 30, 2013
indacaterol-glycopyrronium Ultibro®; Breezhaler® chronic obstructive pulmonary disease (COPD) June 2, 2015
infliximab Inflectra® ; Renflexis™; Remicade® ankylosing spondylitis,psoriatic arthritis, rheumatoid arthritis May 27, 2019
infliximab Inflectra™ ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis February 19, 2016
infliximab Inflectra®; Renflexis™ Crohn’s disease and ulcerative colitis September 5, 2019
ingenol mebutate Picato® keratosis, actinic June 5, 2014
insulin degludec Tresiba® type 1 & 2 diabetes mellitus June 12, 2008
insulin degludec and liraglutide Xultophy® type 2 diabetes March 13, 2020
insulin glargine Basaglar™; Lantus® type 1 & 2 diabetes mellitus May 27, 2019
insulin glargine and lixisenatide Soliqua™ type 2 diabetes March 13, 2020
insulin glulisine Apidra™ type 1 & 2 diabetes mellitus June 1, 2009
interferon beta-1a Rebif® clinically isolated syndrome (MS) March 25, 2014
interferon beta-1b injection Betaseron® early treatment before a definite diagnosis of multiple sclerosis July 8, 2008 
isotretinoin Epuris™ treatment of severe acne October 10, 2013 
ivabradine Lancora™ heart failure October 30, 2018
ivacaftor Kalydeco™ cystic fibrosis (CF) in patients with G551D mutation March 11, 2015
ivermectin Rosiver™ inflammatory lesions of rosacea in adults 18 years of age and older September 27, 2016
ixekizumab Taltz™ psoriatic arthritis May 27, 2019
ixekizumab Taltz™ severe plaque psoriasis March 6, 2018
lamotrigine Lamictal® and generics bipolar disorder November 12, 2019
latanoprost Monoprost® reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension January 28, 2020
ledipasvir-sofosbuvir Harvoni™ chronic hepatitis C (CHC) March 13, 2018
levodopa + carbidopa + entacapone Stalevo® hard-to-treat Parkinson’s disease June 5, 2009
levofloxacin Levaquin® short-course airway infections January 14, 2009
levofloxacin Quinsair cystic fibrosis October 16, 2018
linagliptin; linagliptin-metformin Trajenta®; Jentadueto™ type 2 diabetes mellitus August 5, 2014
lixisenatide Adlyxine™ type 2 diabetes mellitus  June 12, 2018
lomitapide Juxtapid™ to reduce high cholesterol caused by homozygous familial hypercholesterolemia (HoFH) June 23, 2015
lovastatin + niacin Advicor® high cholesterol March 3, 2008
lumacaftor-ivacaftor Orkambi cystic fibrosis (CF) in patients with F508del mutation March 21, 2017
lurasidone Latuda™ schizophrenia September 19, 2013
lurasidone Latuda™ schizophrenia September 16, 2014 
macitentan Opsumit™ pulmonary arterial hypertension January 26, 2016
mepolizumab Nucala™ severe eosinophilic asthma October 29, 2019
mesalazine Mezera™ ulcerative colitis and ulcerative proctitis February 26, 2019
methadone Metadol-D® opioid use disorder March 26, 2019
mifepristone and misoprostol Mifegymiso for medical termination of a developing intra-uterine pregnancy with a gestational age up to 49 days as measured from the first day of the last menstrual period (LMP) in a presumed 28-day cycle July 11, 2017
mirabegron Myrbetriq overactive bladder August 4, 2016
moxifloxacin Avelox® airway infections January 15, 2009
mycophenolate mofetil  Teva-Mycophenolate Bullous Pemphigoid and Autoimmune Hepatitis November 26, 2019
natalizumab Tysabri® relapsing remitting multiple sclerosis March 26, 2019
nebivolol Bystolic® hypertension, essential March 25, 2014
netupitant-palonosetron Akynzeo™ For the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult patients November 26, 2019
nintedanib Ofev® idiopathic pulmonary fibrosis (IPF) February 6, 2018
obeticholic acid Ocaliva® primary biliary cholangitis October 30, 2018
ocriplasmin Jetrea® symptomatic vitreomacular adhesion January 27, 2015
omalizumab Xolair® chronic idiopathic urticarial November 29, 2016
ombitasvir-paritaprevir-ritonavir and dasabuvir Holkira™Pak chronic hepatitis C (CHC) genotype 1 infection July 28, 2015
onabotulinumtoxinA Botox® prevention of headaches in adults with chronic migraine November 18, 2014
onabotulinumtoxinA Botox® overactive bladder February 26, 2019
oxybutynin (controlled-release) Uromax® overactive bladder February 27, 2008
ozenoxacin Ozenax™ impetigo April 9, 2019
palonosetron hydrochloride Aloxi® capsule nausea and vomiting (chemotherapy induced) prevention October 31, 2013
palonosetron hydrochloride Aloxi® injection nausea and vomiting (chemotherapy induced) prevention October 31, 2013
pasireotide Signifor® treatment of adult patients with Cushing's disease for whom medical therapy is appropriate September 1, 2015
pegfilgrastim Fulphila™ to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs February 11, 2020
pegfilgrastim Lapelga decrease infection with febrile neutropenia for non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs July 9, 2019
peginterferon beta-1a Plegridy multiple sclerosis (MS), relapsing August 4, 2016
pegvisomant Somavert® last line of treatment for acromegaly January 14, 2014
perampanel Fycompa™ epilepsy, partial onset seizures August 15, 2014
perindopril arginine-amlodipine Viacoram® essential hypertension July 25, 2017
pirfenidone Esbriet™ idiopathic pulmonary fibrosis (IPF) January 14, 2014
propiverine  Mictoryl®  overactive bladder (OAB) March 20, 2018
propranolol hydrochloride Hemangiol™ proliferating infantile hemangioma January 29, 2019
ramipril + hydrochlorothiazide Altace HCT® hypertension December 17, 2008
rifaximin Zaxine® hepatic encephalopathy February 6, 2018
riociguat Adempas® chronic thromboembolic pulmonary hypertension (CTEPH) March 10, 2015
riociguat Adempas® pulmonary arterial hypertension (PAH) May 2, 2017
rituximab Rituxan® relapsing remitting multiple sclerosis November 27, 2018
rivaroxaban Xarelto® thromboembolic events (venous), pulmonary embolism (PE) September 30, 2014
rotigotine Neupro® Parkinson's disease  November 13, 2018
sacubitril-valsartan Entresto™ heart failure March 6, 2018
sarilumab Kevzara rheumatoid arthritis October 17, 2017
saxagliptin; saxagliptin-metformin Onglyza®; Komboglyze™ type 2 diabetes mellitus  August 5, 2014
secukinumab Cosentyx® psoriasis, moderate to severe plaque July 28, 2016
secukinumab Cosentyx® psoriatic arthritis April 24, 2018
selexipag Uptravi® pulmonary arterial hypertension October 30, 2018
simeprevir Galexos™ chronic hepatitis C (CHC) genotype 1 infection October 28, 2014
sitagliptin; sitagliptin-metformin Januvia®; Janumet®; Janumet® XR type 2 diabetes mellitus  August 5, 2014
sofosbuvir Sovaldi® chronic hepatitis C (CHC) March 13, 2018
sofosbuvir-velpatasvir Epclusa™ chronic hepatitis C (CHC) March 13, 2018
sofosbuvir-velpatasvir-voxilaprevir Vosevi™ chronic hepatitis C (CHC) March 13, 2018
somatropin Genotropin® growth hormone deficiency, adults August 5, 2014
somatropin Genotropin® growth hormone deficiency, pediatrics August 5, 2014
somatropin Genotropin® growth hormone deficiency, Turner syndrome August 5, 2014
somatropin Omnitrope® growth hormone deficiency or chronic renal insufficiency, pediatric April 10, 2018
stiripentol Diacomit™ severe myoclonic epilepsy in infancy (Dravet syndrome) July 7, 2015
tapentadol Nucynta® severe pain May 22, 2019
teduglutide  Revestive® short bowel syndrome (SBS) August 15, 2017
telaprevir Incivek® chronic hepatitis C virus infection in patients co-infected with HIV October 10, 2013
telbivudine Sebivo® chronic hepatitis B infection in patients with liver disease March 27, 2008
tenofovir alafenamide fumarate Vemlidy™ chronic hepatitis B December 18, 2018
tenofovir disoproxil fumarate Viread® chronic hepatitis B November 27, 2018
teriflunomide Aubagio™ relapsing-remitting multiple sclerosis (RRMS) December 9, 2014
tesamorelin Egrifta® excess visceral adipose tissue (VAT) in treatment-experienced adult human immunodeficiency virus (HIV)-infected patients with lipodystrophy December 13, 2016
ticagrelor Brilinta® for use in combination with low-dose acetylsalicylic acid (ASA) for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurring at least one year ago) and a high-risk of developing an atherothrombotic event September 5, 2017
tinzaparin Innohep® venous thromboembolism (VTE) associated with cancer February 14, 2017
tiotropium bromide Spiriva® Respimat® chronic obstructive pulmonary disease (COPD) April 5, 2016
tiotropium-olodaterol Inspiolto™ Respimat® chronic obstructive pulmonary disease (COPD) April 5, 2016
tocilizumab Actemra® moderate to severely active polyarticular juvenile idiopathic arthritis (pJIA) December 9, 2014
tocilizumab Actemra® rheumatoid arthritis February 19, 2016
tocilizumab Actemra® giant cell arteritis March 12, 2019
tofacitinib Xeljanz™ rheumatoid arthritis January 31, 2017
tolvaptan Samsca® hyponatremia, non-hypovolemic August 15, 2013
travoprost ophthalmic solution Izba™ open-angle glaucoma May 29, 2018
ulipristal acetate Fibristal® uterine fibroids October 2, 2018
umeclidinium Incruse™ Ellipta® chronic obstructive pulmonary disease (COPD) March 15, 2016
umeclidinium-vilanterol Anoro™ Ellipta™ chronic obstructive pulmonary disease (COPD) August 11, 2015
ustekinumab Stelara® treatment of moderate to severe psoriatic arthritis (PsA) May 26, 2015
ustekinumab Stelara® Crohn's disease August 27, 2019
vancomycin oral vancomycin Clostridium difficile infection December 18, 2019
vedolizumab Entyvio™ Crohn's disease May 2, 2017
vedolizumab Entyvio™ ulcerative colitis May 2, 2017

 

Subject of Review 

Drugs Included in Review

Date

Supporting Information and Documents

Alzheimer’s disease

  • Donepezil (ARICEPT and generics)
  • Galantamine (REMINYL ER and generics)
  • Rivastigmine (EXELON and generics)

April 2016

Alzheimer's Drug Therapy Review Reports and DBC Recommendation 

Attention Deficit Hyperactivity Disorder (ADHD)

  • atomoxetine (STRATTERA and generics)
  • dextroamphetamine (DEXEDRINE and generics)
  • dextroamphetamine sustained-release (DEXEDRINE SPANSULES)
  • guanfacine (INTUNIV XR) 
  • lisdexamfetamine (VYVANSE)
  • methylphenidate controlled-release (BIPHENTIN)
  • methylphenidate extended-release (CONCERTA and generics)
  • methylphenidate (RITALIN and generics)
  • methylphenidate sustained-release (RITALIN SR and generics)
  • mixed amphetamine salts (ADDERALLL XR and generics)

April 2017

Drug Decision Summary (PDF)

Drug Therapy Review Reports and DBC Recommendation

Overactive Bladder (OAB)

  • darifenacin (ENABLEX)
  • fesoterodine (TOVIAZ)
  • mirabegron extended release (MYRBETRIQ)
  • solifenacin (VESICARE and generics)
  • Tolterodine extended release (DETROL LA and generics)

August 2016

Drug Decision Summary and DBC Reasons and Recommendations (PDF)

Clinical Evidence Report (PDF)

Pharmacoeconomic Evidence Report (PDF)

Reference Drug Program

All drugs covered under the Reference Drug Program:

  • angiotensin-converting-enzyme Inhibitors
  • angiotensin receptor blockers
  • dihydropyridine calcium channel blockers 
  • histamine2 receptor blockers
  • HMG-CoA reductase inhibitors (Statins)
  • nitrates
  • non-steroidal anti-inflammatory drugs (NSAIDs)
  • proton pump inhibitors (PPIs)

June 2016                   

RDP Review Reports and DBC Recommendation